The FINANCIAL — Bristol-Myers Squibb Company and Dana-Farber Cancer Institute on February 16 announced that they have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. Dana-Farber Cancer Institute is the latest leading, academic-based cancer center to join the I-O RPM program, which is a multi-institutional initiative focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
“Dana-Farber Cancer Institute and Bristol-Myers Squibb have a shared commitment to patients and to continuing to advance the science in Immuno-Oncology research,” said Laura Bessen, MD, head of U.S. Medical, Bristol-Myers Squibb. “We look forward to working with them as part of the I-O RPM program.”
“Recent advances in scientific research have shown the great potential of immuno-oncology agents in hematologic cancers, including myeloma,” commented Dr. Paul Richardson, Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. “We look forward to expanding on these findings through the support of the I-O RPM program with the goal of further improving patient outcomes.”
As part of the I-O RPM program, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early phase clinical studies and Bristol-Myers Squibb will support the training of young investigators who contribute to the I-O RPM program at Dana-Farber, according to Bristol-Myers Squibb.
Discussion about this post